Cost analysis of the treatment of schizophrenia in Thailand: A simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol

Journal of the Medical Association of Thailand

Volumn 88, Issue 9, 2005, Pages 1267-1277

  Kongsakon, Ronnachai ^a   Leelahanaj, Thawatchai ^b   Price, Natalia ^c   Birinyi Strachan, Liesl ^c   Davey, Peter ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Phramongkutklao Hospital   (Thailand)

^c Medical Technology Assessment Group Pty Ltd   (Australia)

Author keywords

Atypical antipsychotics; Cost analysis; Haloperidol; Olanzapine; Quetiapine; Risperidol; Schizophrenia; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CALCULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; PRODUCTIVITY; PUBLICATION; RECURRENCE RISK; REVIEW; SCHIZOPHRENIA; SUICIDE ATTEMPT; THAILAND; TIME SERIES ANALYSIS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COMPUTER SIMULATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIBENZOTHIAZEPINES; DRUG COSTS; HALOPERIDOL; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMETRIC; PIPERAZINES; RISPERIDONE; SCHIZOPHRENIA; THAILAND; THIAZOLES; TREATMENT OUTCOME;

EID: 31544472610     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Thieda P, Beard S, Richter A, Kane J. An Economic Review of Compliance with Medication Therapy in the Treatment of Schizophrenia. Psychiatr Serv 2003; 54: 508-16.
2. Barbato A. Schizophrenia and public health Geneva: World Health Organization, 1998.
3. World Health Report. Geneva, Switzerland: World Health Organization, 2001.
4. Lemon MD. Two New Atypical Antipsychotics: Advantages and Disadvantages. South Dakota SU 1998; 51: 285-6.
5. Kongsakon R, Roungkarnjanaset S. Olanzapine versus Haloperidol in the treatment of refractory schizophrenia: A cost-effectiveness analysis. J Psychiatr Assoc Thailand 2000; 45: 71-85.
6. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD. Doubleblind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-18.
7. Conley RR, Mahmoud R. A randomized doubleblind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psych 2001: 158: 765-4.
8. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for Research in Schizophrenia. Arch General Psychiatry 2000; 57: 249-58.
9. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003; 11: 638-47.
10. Gureje O, Miles W, Keks N. Olanzapine versus risperidone in the management of schizophrenia: A randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003: 61: 303-14.
11. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine vs placebo and haloperidol: acute phase results of the North American double-blindolanzapinetrial. Neuropsy chopharmacology 1996; 14: 111-23.
12. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson G, Tran PV, Beuzen JN, Group TOES. Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Neuropsychopharmacology 1996; 7: 125-37.
13. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizo phreniform disorders: results of an international collaborative trial. Am J Psych 1997; 154: 457-65.
14. Lieberman JA, Tollefson G, Tohen M, Green A. Comparative efficacy and safety of conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psych 2003; 160: 1369.
15. Zhang F, Taylor C, Kurtz D, Tran P. Efficacy, safety and pharmacokinetics of olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia from Taiwan and Taiwan. Eli Lilly. Data on file.
16. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J of Psychiatry 1998; 172: 499-505.
17. Altamura AC, Velona I, Curreli R, Bravi D. Olanzapine in the treatment of paranoid schizophrenia. Eur Neuropsychopharmacol 1999; 9(Suppl 5):s297.
18. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996; 16: 38-44.
19. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre doubleblind comparative study. Acta Psych Scand 1992; 85: 295-305.
20. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26: 121-4.
21. Chouinard G, Jones B, Remington G, Bloom D, Addington D, McEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40.
22. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J of Psych 1994; 151:825-35.
23. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psych 1995; 166: 712-26.
24. Emsley RA. Risperidone in the treatment of firstepisode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophrenia Bulletin 1999; 25: 721-9.
25. Mesotten F. Risperidone versus haloperidol in the treatment of chronic psychotic patients: a multicentre double-blind study. Clin Research Report. In: RIS-INT-2, N 85163, 1991.
26. Min SK, Rhee CS, Kim CE, Kang DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group doubleblind comparative trial. Yonsei Med J 1993; 34: 179-90.
27. Wirshing DA, Marshall BD. Green MF Risperidone in treatment-refractory schizophrenia. Am J Psych 1999; 156: 1374-9.
28. Liu SK, Chen WJ, Chang CJ, Lin HN. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacol 2000; 22: 311-9.
29. Cavallaro R, Mistretta P, Cocchi F, Manzato M, Smeraldi E. Differential efficacy of risperidone versus haloperidol in psychological subtypes of subchronic schizophrenia. Human Psychopharmacol Clin Experimentation 2001; 16: 439-48.
30. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry 1997; 42: 233-46.
31. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomised comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychological Med 2000; 30:95-105.
32. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15: 121-31.
33. Murasaki M, Koyama T, Yamauchi T. Clinical evaluation of quetiapine in schizophrenia - efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia. Presentation at the Annual Meeting of the World Psychiatric Association, 1999.
34. Purdon SE, Malla A, Labelle A, Lit E. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neuroscience 2001; 26: 137-49.
35. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner K, Law GC, Ko GN. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalised patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18: 296-304.
36. Hirsch SR, Kissling W, Baumi J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable chronic schizophrenia. J Clin Psychiatry 2002; 63: 516-23.
37. Foster RH, Goa KL. Olanzapine: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999; 15: 611-40.
38. Ascher-Svanum H, Zhu B, Faries D, Ernst FR. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Annals of General Hospital Psychiatry 2004; 3: 11.
39. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia. CNS Drugs 2002; 16: 473-84.